Answers are grounded in this paper and cite their sources.
Randomized trial shows reduced kidney failure and cardiovascular events in type 2 diabetes with nephropathy, indicating potential treatment benefits.
In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years. (Funded by Janssen Research and Development; CREDENCE ClinicalTrials.gov number, NCT02065791.).
No takes yet. Share an insight, caveat, or question.
Perkovic et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: